AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01989156 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: THS 2.2 Menthol (mTHS 2.2)
Description: THS 2.2 Menthol ad libitum for 5 days in confinement prolonged by 86 days in an ambulatory setting
Study NCT01989156 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Menthol Conventional Cigarette (mCC)
Description: Subject's own preferred brand of mCC ad libitum for 5 days in confinement prolonged by 86 days in an ambulatory setting
Study NCT01989156 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Smoking Abstinence (SA)
Description: SA for 5 days in confinement prolonged by 86 days in an ambulatory setting
Study NCT02746783 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Single dose MUTAGRIP® influenza vaccine
Description: All subjects will receive either a single or double doses of MUTAGRIP® containing A/California/7/2009 (H1N1); A/Texas/50/2012 (H3N2); B/Massachusetts/2/2012. The double dose regimen will be administered at the same time.
Study NCT02746783 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Double dose of MUTAGRIP® influenza vaccine
Description: All subjects will receive either a single or double doses of MUTAGRIP® containing A/California/7/2009 (H1N1); A/Texas/50/2012 (H3N2); B/Massachusetts/2/2012. The double dose regimen will be administered at the same time.
Study NCT03164876 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AUT00206
Description: 4 capsules of 200mg AUT00206, twice daily, to take orally with food for 4 weeks
Study NCT03164876 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4 capsules of placebo, twice daily, to take orally with food for 4 weeks
Study NCT02537561 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Study NCT04675216 — intervention group
Intervention type: PROCEDURE
Intervention: Posterior fossa intracranial pressure measurement
Description: Measurement of posterior fossa pressure in an invasive way
Study NCT00218517 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selegiline hydrochloride
Description: Daily oral selegiline, 5 mg po qd x 7 days, then 5 mg po bid for 7 weeks
Study NCT00218517 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo capsules using blue 00 capsules
Study NCT02525367 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active control condition
Description: The active control condition consists of cognitive activities that do not intend to train cognitive functions based on 'cristallized intelligence', such as trivia. Both the intervention protocol and the active control condition will contain several games that have the participant train cognitive functions/perform cognitive activities for 8 weeks, 3 times a week, 45-60 minutes each session.
Study NCT02002429 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intra-articular injection
Description: Intra-articular injection into the affected facet joint(s) with 0.5 ml of a 50:50 solution containing 10 mg of depo-methylprednisolone and 0.5% bupivacaine. If the subject has a positive block a radiofrequency denervation will be performed at the affected joint.
Study NCT03585452 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine Infusion
Description: Patients with additional dexmedetomidine infusion
Study NCT03585452 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol based general anesthesia
Description: Patients with typical anaesthetic regimens
Study NCT01742793 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide (Revlimid) and romidepsin (Istodax)
Study NCT01076829 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Spice polyphenols
Description: spice
Study NCT01076829 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Spice polyphenols
Description: spice
Study NCT00606723 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hematopoietic stem cells from bone marrow or peripheral blood
Description: > = 2 x 10\*8 nucleated cells (WBC)/kg body weight of the recipient or rather > = 4 x 10\*6 nucleated CD34+ cells / kg body weight are required for engraftment. Suspension of stem cells is administered via intravenous infusion.
Study NCT02537561 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Study NCT03533387 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MN-166
Description: an orally available small molecule drug approved in Japan and Korea for asthma and post-stroke complications and has been prescribed for these indications for more than 25 years
Study NCT03533387 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MN-166
Description: an orally available small molecule drug approved in Japan and Korea for asthma and post-stroke complications and has been prescribed for these indications for more than 25 years
Study NCT02803918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lixisenatide (AVE0010)
Description: Pharmaceutical form: solution~Route of administration: subcutaneous
Study NCT02803918 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form: solution~Route of administration: subcutaneous
Study NCT02803918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Basal Insulin
Description: Pharmaceutical form: solution~Route of administration: subcutaneous
Study NCT02803918 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Basal Insulin
Description: Pharmaceutical form: solution~Route of administration: subcutaneous
Study NCT02803918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Pharmaceutical form: tablet~Route of administration: oral
Study NCT02537561 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib
Study NCT02803918 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Description: Pharmaceutical form: tablet~Route of administration: oral
Study NCT01224639 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TDV - Low Dose
Description: TDV is a tetravalent dengue vaccine comprised of four recombinant, live attenuated dengue virus strains: TDV-1, TDV-2, TDV-3 and TDV-4. Low dose contains: TDV-1: 8 x 10\^3 PFU, TDV-2: 5 x 10\^3 PFU, TDV-3: 1 x 10\^4 PFU, and TDV-4: 2 x 10\^5 PFU, total virus per dose 2.2 x 10\^5 PFU
Study NCT01224639 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TDV - High Dose
Description: TDV is a tetravalent dengue vaccine comprised of four recombinant, live attenuated dengue virus strains: TDV-1, TDV-2, TDV-3 and TDV-4. High dose contains TDV-1: 2 x 10\^4 PFU, TDV-2: 5 x 10\^4 PFU, TDV-3: 1 x 10\^5 PFU, and TDV-4: 3 x 10\^5 PFU, total virus per dose : 4.7 x 10\^5 PFU. TDV administered intradermally.
Study NCT01224639 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Phosphate Buffered Saline (PBS)
Study NCT03181542 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Infrared illumination
Description: Infrared illumination of veins using the FDA approved AccuVein (AccuVein, Inc., Huntington, NY) device.
Study NCT03467633 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-intensity interval training
Description: Participants in the HIIT group will receive 3-weeks of tri-weekly supervised exercise sessions at the UOHI prior to their scheduled electro-cardioversion. The session will last 23 minutes in duration and consist of a 2-minute warm-up at 50% of peak power output (PPO), 2 x 8-minute interval training blocks of 30 seconds at 80-100% of PPO interspersed with 30-seconds of active recovery and a 1-minute cool down at 25 % of PPO. The sessions will be lead by a Registered Kinesiologist.
Study NCT00247728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PI-88
Description: Once-daily SC injection for four consecutive days per week, for 3 weeks out of every 4 weeks
Study NCT03424031 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Verticalization
Description: To allow the verticalization of hemiplegic patients, we will use a device commonly used in rehabilitation: the standing (or standing) brand Thera Trainer . This device makes it possible to keep the patient standing despite the motor and postural deficits thanks to knee, buttocks and an anterior support for the upper limbs. Verticalization with this device requires the presence of one or two caregivers (including at least one re-educator), depending on the possibilities of participation of the patient.
Study NCT01920815 — intervention group
Intervention type: OTHER
Intervention: No interventions
Study NCT03366064 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pemetrexed and donor-derived NK cell infusion
Description: Patients are administered with donor-derived NK cells one week after pemetrexed infusion
Study NCT01924169 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: 5 mg/day by mouth on Monday, Wednesday and Friday for 3 months. Process repeated for up to 2 years.~If IgG levels do not improve, frequency of lenalidomide increased to 5 mg/day by mouth for additional 3 months and if response is achieved, lenalidomide continued at 5mg/day 3 month on/3 month off for a total of 2 years.
Study NCT01924169 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Vaccine
Description: Administered as injection yearly, during the fall/winter season.
Study NCT01924169 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumovax Vaccine
Description: Administered by injection once between month 6 and month 21. Patients, who have received the Pneumovax vaccine within last 5 years, will not receive Pneumovax vaccination.
Study NCT03821012 — intervention group
Intervention type: OTHER
Intervention: in-hospital process optimization
Study NCT03821012 — intervention group
Intervention type: OTHER
Intervention: PPCI hospital-based regional STEMI transfer network construction
Study NCT03821012 — intervention group
Intervention type: OTHER
Intervention: the whole-city STEMI care network construction
Study NCT02002429 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Medial branch block
Description: Medial branch blocks at the nerves that supply the affected facet joint(s) with 0.5 ml of a 50:50 solution containing 10 mg of depo-methylprednisolone and 0.5% bupivacaine. If the subject has a positive block a radiofrequency denervation will be performed at the affected joint.
Study NCT04007822 — intervention group
Intervention type: BEHAVIORAL
Intervention: Pain Navigator Tool
Description: The Pain Navigator Tool (PNT) was developed recently with the aim to empower patients through helping them to discuss their main concerns about pain, and to help therapists to prioritise addressing these concerns (Blomkvist et al., 2018). The initial pilot study with this tool improved the content of the consultations and patient engagement, and led to better patient-therapist interaction in a small population of healthcare providers and patients (Blomkvist et al., 2018). As it endeavours to facilitate the implementation of self-management in patients with chronic pain, the PNT aligns with the Scottish Intercollegiate Guidelines Network (SIGN) guideline for chronic pain and the Scottish Government's strategic vision (Scottish Government, 2011; SIGN, 2013).
Study NCT00297089 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ABT-751
Description: 200 mg ABT-751 daily for 14 days every 21 days
Study NCT00297089 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pemetrexed
Description: Standard pemetrexed every 21 days
Study NCT00297089 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: pemetrexed
Description: Standard pemetrexed every 21 days
Study NCT00297089 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo daily for 14 days every 21 days
Study NCT00860509 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low Phytosterol and High Phytosterol Diets
Description: Diets with 600 or 100 mg of daily phytosterols for 4 weeks were given to each subject, in random order
Study NCT00860509 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Low Phytosterol and High Phytosterol Diets
Description: Diets with 600 or 100 mg of daily phytosterols for 4 weeks were given to each subject, in random order
Study NCT02002429 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Saline injection
Description: Injection into the affected facet joint(s) with 0.5 ml of normal saline. All subjects in the group will receive radiofrequency denervation.
Study NCT02369380 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid
Description: Injections of Hyaluronic acid under the metatarsal heads
Study NCT01618357 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Patients will receive radiation therapy at a dose of 2.35 Gy per fraction to the breast and regional nodal region for 16 fractions to a total dose of 37.5 Gy. Treatments will be given Monday through Friday. Radiation therapy will start on day 1 of Veliparib.
Study NCT01618357 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumpectomy/Mastectomy
Description: Resection of breast cancer.
Study NCT01618357 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Veliparib
Description: Pills to be taken twice a day during radiation and for one week after completion of radiation for a total of 29 days.
Study NCT04365699 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AT-001
Description: Investigational novel Aldose Reductase Inhibitor (ARI) Product: AT-001 500mg capsule for oral administration Dosage: 1,500mg (3X500mg capsules) twice daily Mode of Administration: Oral Up to 14 days per discretion of the investigators and treatment team
Study NCT02995785 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: simulation-based training
Description: simulation-based training:The first aid skill simulation training with discussion and debriefing(75-min) and TMS online lecture(15-min).
Study NCT02995785 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: traditional training
Description: traditional training:Give TMS online lecture(15-min).
Study NCT02752932 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Drug testing on PDX per Investigator's choice (upto 4)
Description: Drug of Investigator's choice (upto 4 Ontario funded Chemotherapeutics) will be tested on PDX (Patient Derived Xenografts)
Study NCT01346267 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Real Acupressure Band
Description: Acupressure wristband
Study NCT01346267 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Placebo Acupressure Band
Description: Sham wristband
Study NCT03671291 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: self-administrated questionnaire
Description: Persons who the biological parameters or past screening show that they were recently infected with HIV cf. eligibility criteria, will, after obtaining his consent, answer a series of questions through a self-administrated questionnaire that will take approximately 40 minutes.
Study NCT01346384 — intervention group
Intervention type: DEVICE
Intervention: laryngeal tube (VBM Medizintechnik)
Description: laryngeal tube number 4
Study NCT02696096 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: FMRI
Description: all participants will complete 2 FMRIs
Study NCT02696096 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Suboxone
Description: all participants will be prescribed Suboxone for 4 months during their study participation
Study NCT03933241 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: nasal irrigation
Description: nasal irrigation after Transnasal transsphenoidal surgery for pituitary tumor
Study NCT00134056 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atrasentan hydrochloride
Description: Given orally
Study NCT00134056 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: docetaxel
Description: Docetaxel given IV and prednisone given orally
Study NCT00134056 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Docetaxel given IV and prednisone given orally
Study NCT00134056 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisone
Description: Docetaxel given IV and prednisone given orally
Study NCT00134056 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: Docetaxel given IV and prednisone given orally
Study NCT00134056 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: Given orally
Study NCT02951702 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin Oral
Description: This arm will receive oral vancomycin 125 mg daily if high risk and determined to be appropriate by an ID physician
Study NCT01769729 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PEPP
Study NCT01769729 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Care management
Study NCT01769729 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Care management
Study NCT01426217 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Passive Bundle PSI (Problem Solving Innovations) Medical HubScrub, PSI Medical DocIt
Description: Implementation of passive bundle which includes HubScrub and DocIt device into the operating room environment.
Study NCT02555397 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad5-yCD/mutTKSR39rep-hIL12
Description: Single intraprostatic injection of Ad5-yCD/mutTKSR39rep-hIL12 on day 1
Study NCT04021277 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 20 uL/kg PS101
Description: 20 uL/kg PS101 and chemotherapy given for 4 cycles over 6 weeks
Study NCT04021277 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 40 uL/kg PS101
Description: 40 uL/kg PS101 and chemotherapy given for 4 cycles over 6 weeks
Study NCT04021277 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: Ultrasound activation and enhancement
Study NCT02900937 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AmM MAGNITUDE Bioresorbable Drug-Eluting Coronary Scaffold
Description: Placement of the investigational device into the diseased coronary artery to eliminate the vascular stenosis.
Study NCT02380599 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spinal Manipulation
Description: Mid-thoracic spinal manipulation to T3-5 region
Study NCT02380599 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spinal Mobilization
Description: Mid-thoracic spinal mobilization to T3-5 region
Study NCT02380599 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sham Ultrasound
Description: Sham ultrasound to T3-5 region
Study NCT04913584 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy
Description: Cognitive Behavioral Therapy 9 weekly 2-hour online group CBT sessions delivered by trained lay peers.
Study NCT02121691 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walk by Faith
Description: The Walk by Faith program is aimed at increasing physical activity and improving healthy eating to reduce or maintain healthy BMI among members of the churches.
Study NCT01076530 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vorinostat
Study NCT01076530 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide
Study NCT01076530 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: diagnostic laboratory biomarker analysis
Study NCT03331692 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: monitoring of the proper level of general anesthesia
Description: The monitoring of the adequate level of general anesthesia was performed both clinically and instrumentally.
Study NCT01156285 — intervention group
Intervention type: OTHER
Intervention: Filling in a patient questionnaire
Description: Filling in a patient questionnaire
Study NCT01786629 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SUPREP Bowel Prep Kit
Description: solution for oral administration prior to colonoscopy
Study NCT01786629 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FDA approved bowel preparation containing electrolytes
Description: solution for oral administration prior to colonoscopy
Study NCT05514067 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electro-Acupuncture
Description: A single application of EA at cardiac-related acupoints administered for 30 min prior to CABG surgery.
Study NCT01565031 — intervention group
Intervention type: PROCEDURE
Intervention: Step-wise down-titration according to international guidelines.
Description: The medication will be adjusted according to each patient´s level of control. Depending on the state of control of asthma, the dose will be adjusted up or down (step-up therapy and step-down therapy, respectively) in accordance with GINA.
Study NCT01075815 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human luteinizing hormone (rhLH)
Study NCT01075815 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant follicle-stimulating hormone (rFSH)
Study NCT01075815 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant follicle-stimulating hormone (rFSH)